Researchers in this program take advantage of the Institute’s high-throughput screening and analysis facility in the
Conrad Prebys Center for Chemical Genomics to identify chemical compounds that inhibit the cellular processes that allow cancer cells to proliferate. While much of our research is focused on cancer, these studies also have clear relevance to a number of other diseases, especially inflammatory and nervous system disorders.
The program is also home to Sanford-Burnham’s
Vascular Mapping Center—where phage display technology is used to identify peptides that home to individual tumors. An additional strength of the program is its strong expertise in glycosylation, a cellular process fundamental to many different diseases.
How our research helps improve health
Research in this program, combined with that of the other programs in the NCI-designated Cancer Center and the Conrad Prebys Center for Chemical Genomics, holds potential for the discovery of new cancer drugs and more safe and effective ways to deliver those drugs to the affected areas while minimizing side effects.